As CD1d expression in CLL appears to increase in more advanced stages of the disease,19 it is tempting to speculate that CLL cells exploit the use of a distinct lipid repertoire in CD1d to circumvent type 1 NKT cell recognition, potentially in favor of recognition by pro-tumor diverse NKT cell populations. The gene discussed is CD1D; the disease is neoplasm.